Here are 1-3 brief analogies for PharmaCyte Biotech (PMCB):

• Moderna, but for encapsulated living cells rather than mRNA, targeting cancer and diabetes.
• A smaller, early-stage Novartis focused on developing a proprietary 'Cell-in-a-Box' technology for cellular therapies against cancer and diabetes.

• Cellular Therapies for Pancreatic and Other Tumors: These therapies utilize the proprietary Cell-in-a-Box encapsulation technology with genetically modified living cells to treat various cancers, including advanced and inoperable non-metastatic pancreatic cancer.
• Cellular Therapies for Type 1 and Insulin-Dependent Type 2 Diabetes: Developed using the Cell-in-a-Box platform, these therapies aim to treat both Type 1 and insulin-dependent Type 2 diabetes.
• Cannabis-Based Therapies for Cancer: These are therapies under development that leverage the constituents of the cannabis plant for cancer treatment.

Based on the provided company description, PharmaCyte Biotech (PMCB) is a biotechnology company primarily focused on developing and commercializing cellular therapies for cancer and diabetes. The background information indicates that the company is largely engaged in the research and development phase of its proprietary "Cell-in-a-Box" technology and associated therapies.

As of the provided description, no specific major commercial customers are identified as currently purchasing PharmaCyte Biotech's products or therapies. Biotech companies at this stage often do not have major commercial customers in the traditional sense, as their products are typically undergoing extensive clinical trials and awaiting regulatory approval.

However, once PharmaCyte Biotech's therapies are fully developed, approved, and ready for market, its customer base would primarily consist of companies and institutions within the healthcare sector. The categories of customers it would likely serve include:

1. Healthcare Providers: This category encompasses hospitals, specialized clinics (e.g., oncology centers, diabetes treatment centers), and individual medical practitioners (oncologists, endocrinologists) who would purchase and administer the approved cellular therapies to patients.
2. Pharmaceutical Distributors/Wholesalers: These companies would play a crucial role in the supply chain, handling the storage, logistics, and distribution of the therapies from PharmaCyte Biotech to various healthcare providers.
3. Pharmaceutical Partners: PharmaCyte Biotech may enter into licensing agreements, co-development deals, or distribution partnerships with larger pharmaceutical companies. In such scenarios, these larger pharma companies would effectively be "customers" for PharmaCyte Biotech's intellectual property, developed therapies, or manufacturing capabilities, enabling broader market reach.

Given the nature of advanced cellular therapies for complex diseases, PharmaCyte Biotech does not appear to sell its products directly to individual consumers or patients.

Joshua N. Silverman – Interim Chief Executive Officer, President, and Director

Joshua N. Silverman currently serves as the Interim CEO, President, and a Director of PharmaCyte Biotech, and has also been the Interim Chairman of the Board since October 2022. He is the Co-Founder and Managing Member of Parkfield Funding LLC and was a Principal and Managing Partner of Iroquois Capital Management, LLC, where he served as Co-Chief Investment Officer from 2003 until July 2016. Prior to Iroquois, he was Co-Chief Investment Officer of Vertical Ventures, LLC, a merchant bank, from 2000 to 2003. Mr. Silverman also worked as a Director at Joele Frank, a consulting firm specializing in mergers and acquisitions, and previously served as Assistant Press Secretary to The President of The United States. He currently sits on the boards of directors for Ayro Inc., MYMD Pharmaceuticals, Inc., Petros Pharmaceuticals, Inc., and Synaptogenix, Inc. PharmaCyte Biotech recently monetized its stake in Femasys Inc., an entity where Mr. Silverman serves on the board.

Carlos A. Trujillo, CPA – Chief Financial Officer

Carlos A. Trujillo is the Chief Financial Officer of PharmaCyte Biotech and also serves as the Principal Accounting Officer and a member of PharmaCyte's Board of Directors. He is a Certified Public Accountant licensed in California with 35 years of experience in finance, accounting, and management. Mr. Trujillo began his career in public accounting as an audit department manager and later operated his own consulting and accounting practice for a decade, providing CFO services to organizations across various industries, including biotechnology, telecommunications, manufacturing, construction, and real estate development. For the past eleven years, he has held CFO positions for both privately-held and publicly-traded multinational companies, bringing extensive experience in preparing and filing periodic reports with the Securities and Exchange Commission, mergers and acquisitions, and comprehensive financial statement reporting.

Dr. José Iglesias M.D. – Consulting Chief Medical Officer

Dr. José Iglesias serves as the Consulting Chief Medical Officer for PharmaCyte Biotech. He contributes a wealth of experience in the development and testing of cancer chemotherapeutic agents, having held key positions at prominent biotechnology firms such as Eli Lilly, Amgen, Abraxis, and Celgene. Notably, as the global Vice-President of Clinical Development at Celgene, Dr. Iglesias was the lead physician for the team that secured FDA approval for Abraxane®, a first-line therapy for pancreatic cancer.

Robert Weinstein – Director

Robert Weinstein has been a director of PharmaCyte Biotech since November 2022. He currently holds the position of Chief Financial Officer at Synaptogenix, Inc. (Nasdaq: SNPX) since October 2013, and also works as a consultant for Petros Pharmaceuticals, Inc. (Nasdaq: PTPI). With over 30 years of experience, Mr. Weinstein's background spans public accounting, investment banking, serving as a principal in a healthcare private equity fund, and various chief financial officer roles. From August 2007 to February 2010, he was the CFO of Xcorporeal, Inc., a development-stage medical device company that was acquired by Fresenius Medical USA in March 2010.

Wayne R. Walker – Director

Wayne R. Walker joined PharmaCyte Biotech's board of directors in December 2022. He brings over 35 years of experience in corporate governance, turnaround management, corporate restructuring, and bankruptcy matters. Since 1998, Mr. Walker has been the founder and president of Walker Nell Partners, Inc., an international business consulting firm.

The key risks to PharmaCyte Biotech (PMCB) are primarily associated with the inherent uncertainties of biotechnology drug development.

1. Clinical Trial and Regulatory Approval Risk: PharmaCyte Biotech's therapies, including those for advanced pancreatic cancer and diabetes, are currently in development and have not yet received regulatory approvals. There is a significant risk that these cellular therapies may fail to demonstrate efficacy or safety in clinical trials, or may not meet the stringent requirements for regulatory approval (e.g., from the FDA). Failure at any stage of the costly and lengthy clinical development process could significantly impede or halt the commercialization of its product candidates.

2. Reliance on a Single Core Technology: The company's entire therapeutic platform is based on its proprietary "Cell-in-a-Box" live cell encapsulation technology. The success of PharmaCyte's pipeline, which aims to treat various cancers and diabetes, is heavily dependent on the continued viability, safety, and efficacy of this specific technology. Any unforeseen limitations, side effects, manufacturing challenges, or failures in the application of the Cell-in-a-Box technology could jeopardize the entire product portfolio.

3. Financing Risk and Capital Needs: As a biotechnology company primarily engaged in research and development, PharmaCyte Biotech is likely to incur significant expenses without generating substantial revenue until its therapies are successfully commercialized. Developing and bringing novel cellular therapies to market, especially for complex diseases like cancer and diabetes, requires substantial capital for preclinical studies, clinical trials, regulatory submissions, and potential commercialization efforts. The company faces an ongoing risk of needing to raise additional capital, which may not be available on favorable terms or at all, potentially leading to delays or abandonment of development programs.

PharmaCyte Biotech (PMCB) operates in several significant addressable markets for its cellular therapies:

Pancreatic Cancer Treatment Market

PharmaCyte Biotech is developing cellular therapies for advanced and inoperable non-metastatic pancreatic cancer using its Cell-in-a-Box technology.

• The global pancreatic cancer treatment market was estimated at approximately $2.92 billion in 2024 and is projected to reach $5.84 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 12.3% from 2025 to 2030.
• Other estimates place the global pancreatic cancer market size at $3.54 billion in 2024, expected to reach around $13.93 billion by 2034 with a CAGR of approximately 14.68% between 2025 and 2034.
• Another report indicated the global market was valued at $3.28 billion in 2025 and is likely to cross $12.05 billion by 2035, registering over a 13.9% CAGR.
• North America accounted for the largest share of the pancreatic cancer treatment market in 2024. The U.S. alone accounted for nearly 50% of the total market size among the 7 major markets in 2023.

Cannabis-Based Cancer Therapies Market

PharmaCyte Biotech is also developing therapies for cancer based on constituents of the cannabis plant (cannabinoids), intending to combine these with their Cell-in-a-Box technology for difficult-to-treat cancers.

• The global cannabinoid-based products for cancer market was valued at approximately $2.8 billion in 2023 and is anticipated to reach $9.5 billion by 2033, growing at a CAGR of 12.8% from 2024 to 2033.
• More broadly, the global medical cannabis market was valued at $18.1 billion in 2023 and is projected to reach $122.7 billion by 2032, exhibiting a robust CAGR of 23.7%.
• Other estimations for the global medical cannabis market include $25.86 billion in 2024, expected to reach $133.73 billion by 2032, growing at a CAGR of 22.80%. Another source valued the global medical cannabis market at $39.6 billion in 2025, with an expectation to reach $74.3 billion by 2034 at a CAGR of 6.90%.
• North America holds the largest share in the medical cannabis market.

Diabetes Treatment Market (Type 1 and Insulin-Dependent Type 2 Diabetes)

PharmaCyte Biotech is developing a cellular therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes designed to function as a "bio-artificial pancreas" by producing and releasing insulin.

Type 1 Diabetes Treatment Market

• The global Type 1 Diabetes Treatment market size is projected to grow from $7.2 billion in 2023 to an estimated $12.6 billion by 2032, at a CAGR of 6.5%.
• Another report states the global Type 1 Diabetes Market Size was approximately $16.01 billion in 2024 and is predicted to grow to around $31.48 billion by 2035 with a CAGR of 6.34% from 2025 to 2035.
• A different estimate places the global market size at $37.60 billion in 2025, predicted to increase to approximately $79.14 billion by 2035, expanding at a CAGR of 7.73%.
• North America accounts for approximately 38%–40% of the global Type 1 Diabetes Treatment Market Share.

Insulin-Dependent Type 2 Diabetes Treatment Market

• The global Type 2 Diabetes Mellitus treatment market generated a revenue of $57.47 billion in 2023 and is expected to reach $91.97 billion by 2030, growing at a CAGR of 6.9% from 2024 to 2030.
• Insulin accounted for a significant portion of the revenue within the Type 2 Diabetes Mellitus treatment market.
• North America was the largest revenue-generating market for Type 2 Diabetes Mellitus treatment in 2023.

Expected Drivers of Future Revenue Growth for PharmaCyte Biotech (PMCB)

For PharmaCyte Biotech (PMCB), a clinical-stage biotechnology company with no current commercialized products, future revenue growth over the next 2-3 years is entirely dependent on the successful advancement and potential commercialization of its pipeline therapies. The primary drivers are centered on clinical development and regulatory milestones for its lead product candidates:

1. Advancement of CypCaps for Pancreatic Cancer: A key driver will be the successful resolution of the U.S. FDA clinical hold on its Phase 2b trial for locally advanced, inoperable pancreatic cancer (LAPC) and the subsequent progression of this trial. The company has been actively conducting required studies, including product stability tests and biocompatibility assessments, and initiated pig studies to address FDA concerns. Successful clinical outcomes and further advancement in this program are critical steps toward potential market entry and revenue generation.
2. Progression of Diabetes Therapy Development: The ongoing development of PharmaCyte's therapy for Type 1 and insulin-dependent Type 2 diabetes, utilizing its Cell-in-a-Box encapsulation technology with genetically modified Melligen cells, is another expected driver. Continued preclinical and clinical progress in this program, moving it closer to human trials and eventual commercialization, would contribute to future revenue potential.
3. Achievement of Key Regulatory Milestones: Obtaining significant regulatory milestones, such as successful completion of clinical trial phases and the submission of regulatory applications (e.g., Biologics License Application), will be essential for future revenue. While full market approval and product launch might extend beyond the immediate 2-3 year timeframe, achieving these critical regulatory steps for its lead candidates would de-risk the programs and position the company for eventual revenue generation.

Share Repurchases

• In May 2022, PharmaCyte Biotech's board authorized a share repurchase program for up to $10 million.
• An additional share repurchase program for up to $10 million was authorized by the board in January 2023.

Share Issuance

• PharmaCyte Biotech completed a 1-for-1,500 reverse stock split on July 12, 2021, which reduced the number of outstanding shares from approximately 2.4 billion to about 1.6 million.
• In August 2025, the company closed a $7 million private placement with existing investors, involving the sale of Series C convertible preferred stock and warrants to purchase up to 7,000,000 shares of common stock.
• Shareholders approved an amendment to the 2022 Equity Incentive Plan in October 2025, increasing the number of shares available for awards by 2,250,000.

Inbound Investments

• PharmaCyte closed a $7 million financing round in August 2025, which was led by existing investors through the sale of Series C convertible preferred stock and warrants.

Outbound Investments

• In May 2024, PharmaCyte Biotech made a $7 million strategic investment in MyMD Pharmaceuticals, Inc.
• The company increased its stake in TNF Pharmaceuticals by an additional $3 million in September 2025.
• PharmaCyte successfully monetized its stake in Femasys Inc. by November 2025, which is expected to increase the company's cash and marketable securities to approximately $20 million from $13.3 million as of July 31, 2025.